Table 1 Characteristics of the included studies
Authors | Country | Study design | Group | Sample size | Age (years) | Sex (M/F) | BMI (kg/m2) | Surgical approach (Open /MIS) | Procedure (DG/TG) | Pathological T stage | Lymphadenectomy extent | Scoreb |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Seo et al. 2021 | Korea | Retrospective PSM | CO | 225 | 59 (49–70) | 131/94 | 23.5 (21.1–25.6) | 60/165 | 167/58 | T3/T4a: 100/125 | D1 + /D2: 25/200 | 20/24 |
NCO | 225 | 56 (49–67) | 137/88 | 22.9 (21.0–24.9) | 69/156 | 169/56 | T3/T4a: 111/114 | D1 + /D2: 22/203 | ||||
Murakami et al. 2021 | Japan | Prospective RCT | CO | 122 | 71 (30–90) a | 89/33 | 22.4 (14.8–31.8) | 122/0 | 73/49 | T1/T2/T3/T4: 20/21/42/39 | D2: 122 | - |
NCO | 125 | 74 (45–89) a | 89/36 | 22.2 (14.5–32.1) | 125/0 | 81/44 | T1/T2/T3/T4: 31/21/31/42 | D2: 125 | ||||
Sakimura et al. 2020 | Japan | Retrospective PSM | CO | 70 | 65.0 (37–90) | 46/24 | 22.2 (15.8–30.3) | 41/29 | 45/25 | T0/T1/T2/T3/T4: 1/5/12/32/20 | D1 + /D2 or more: 9/61 | 20/24 |
NCO | 70 | 66.5 (42–94) | 48/22 | 22.4 (16.4–32.6) | 25/45 | 44/26 | T1/T2/T3/T4: 6/16/27/21 | D1 + /D2 or more:14/56 | ||||
Ri et al. 2020 | Japan | Retrospective PSM | CO | 263 | 66.7 ± 11.0 | 176/87 | 22.4 ± 3.6 | 263/0 | 156/107 | T1-2/T3-4: 47/216 | ≤ D1/D1 + /D2 or more: 11/146/106 | 22/24 |
NCO | 263 | 65.7 ± 12.9 | 181/82 | 22.5 ± 3.4 | 263/0 | 151/112 | T1-2/T3-4: 48/215 | ≤ D1/D1 + /D2 or more: 8/146/109 | ||||
Young et al. 2020 | USA | Retrospective | CO | 90 | 69.5 (62–77) | 62/28 | 27.4 ± 6.1 | NA | TG:25, STG: 31 | T3 or T4: 41 | NA | 18/24 |
NCO | 381 | 68 (58–76) | 217/164 | 26.2 ± 5.3 | NA | TG:99, STG: 140 | T3 or T4: 184 | NA | ||||
Kim et al. 2014 | Korea | Retrospective | CO | 80 | 60.9 ± 11.2 | 56/24 | NA | 0/80 | 61/19 | T2/T3: 28/52 | D1 + /D2: 2/78 | 19/24 |
NCO | 66 | 62.2 ± 11.0 | 50/16 | NA | 0/66 | 24/12 | T2/T3: 37/29 | D1 + /D2: 5/61 | ||||
Hasegawa et al. 2013 | Japan | Retrospective PSM | CO | 98 | 69.0 (40–91) | 72/26 | NA | 98/0 | 52/46 | T2/T3/T4a: 30/34/34 | D1 + /D2 or more:12/86 | 17/24 |
NCO | 98 | 68.7 (45–91) | 72/26 | NA | 84/14 | 61/37 | T2/T3/T4a: 34/30/34 | D1 + /D2 or more:13/85 | ||||
Kim et al. 2011 | Korea | Retrospective | CO | 20 | 58.2 ± 9.5 | 17/3 | 23.3 ± 2.3 | 20/0 | 20/0 | T1/T2: 20/0 | ≤ D1 + β/ > D2: 13/7 | 17/24 |
NCO | 17 | 58.6 ± 10.1 | 11/6 | 23.6 ± 2.7 | 17/0 | 17/0 | T1/T2: 16/1 | ≤ D1 + β/ > D2: 15/2 | ||||
Ha et al. 2008 | Korea | Retrospective | CO | 992 | 57.0 ± 11.3 | 681/311 | NA | NA | TG: 75, Others: 917 | early gastric cancer | NA | 19/24 |
NCO | 124 | 56.3 ± 11.3 | 87/37 | NA | NA | TG: 25, Others: 99 | early gastric cancer | NA |